Table of Content

1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increase in Incidence of Chronic Diseases
4.2.2 Rising Reimbursement Policies
4.2.3 High Prevalence of Infectious Diseases
4.3 Market Restraints
4.3.1 Reuse of Lancets
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION (Market Size By Value- USD million)
5.1 By Product Type
5.1.1 Safety Lancet
5.1.2 Homecare Lancet
5.2 By End User
5.2.1 Hospitals
5.2.2 Blood Banks
5.2.3 Home Care
5.2.4 Others
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Becton, Dickinson and Company
6.1.2 F. Hoffmann-La Roche Ltd
6.1.3 B. Braun Melsungen AG
6.1.4 Abbott Laboratories
6.1.5 Terumo Corporation
6.1.6 ARKRAY
6.1.7 Owen Mumford Ltd
6.1.8 Intrinsyk, LLC.
6.1.9 Sagard (Sterimed)
6.1.10 Amkay Products Pvt. Ltd


7 MARKET OPPORTUNITIES AND FUTURE TRENDS